Abstract:Background: Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), a novel betacoronavirus, has caused an outburst of pneumonia cases in Wuhan, China. We report the production of specific IgM and IgG antibodies after the infection of SARS-CoV-2 and its implication for the diagnosis, pathology and the course of the disease as well as the recurrence of positive nucleic acid tests after discharge. Methods: Test results for SARS-CoV-2 IgM and IgG antibodies of 221 confirmed COVID-19 patients were retrospectively examined, and their clinical data were collected and analyzed based on various subgroups. SARS-CoV-2 IgM and IgG antibodies were determined with the chemiluminescence method. Findings: The concentration (S/CO) of SARS-CoV-2 IgM and IgG antibodies peaked on day 19-21 after symptom onset, with a median of 17.38 (IQR 4.39-36.4) for IgM and 5.59 (IQR 0.73-13.65) for IgG. Detection rates reached highest on day 16-18 and day 19-21 for IgM and IgG, which were 73.6% and 98.6%, respectively, with significantly higher concentration of IgG in critically ill patients than in those with mild to moderate disease (P=0.027). The concentration of the antibodies on day 16-21 is not correlated with the course or outcome of the disease (Spearman r < 0.20, P > 0.05). Nasopharyngeal swabs revealed positive SARS-CoV-2 RNA in up to 52.7% of recovered patients after discharge, whose IgG proved to be significantly lower than that of those with negative RNA results (P = 0.009). IgG and IgM were tested twice within 14 days after discharge with a 7-day interval, and the second testing of these antibodies displayed a decrease in concentration of 21.2% (IQR, 11.2%34.48%) for IgG and 23.05% (IQR, -27.96%46.13%) for IgM, without statistical significance between the patients with re-detectable positive RNA results and those with negative RNA results after discharge. However, those with positive results experienced a count decrease in lymphocyte subsets. Interpretation: The concentration of SARS-CoV-2 IgM and IgG antibodies peaked on day 19-21 after symptom onset, and antibody testing on day 16-21 is associated with increased detection rates, but the antibody concentration does not affect the course and outcome of the infection. Recovering patients with re-detectable positive SARS-CoV-2 RNA displayed lower concentration of IgG, but the downward trend of IgG during recovery indicated its limited duration of protection, and the protective effect of IgG remains to be investigated.

SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay

Dynamics and significance of the antibody response to SARS-CoV-2 infection

Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

Sars-Cov-2 Antibodies And Associated Factors At Different Hospitalization Time Points In 192 Covid-19 Cases

One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses

Dynamic Characteristic Analysis of Antibodies in Patients with COVID-19: A 13-Month Study

Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases

Serology Characteristics of SARS-CoV-2 Infection after Exposure and Post-Symptom Onset.

Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel

The Production and Clinical Implications of SARS-CoV-2 Antibodies

Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019

Detection of Antibodies Against the SARS-CoV-2 Spike Protein and Analysis of the Peripheral Blood Mononuclear Cell Transcriptomic Profile, 15 Years after Recovery from SARS.

Test performance evaluation of SARS-CoV-2 serological assays

Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice

SARS-CoV-2 antibody detection in skilled nursing facility residents

SARS-CoV-2 serology: Validation of high-throughput chemiluminescent immunoassay (CLIA) platforms and a field study in British Columbia

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans